Stimulation of Mammary Tumorigenesis and Suppression of Uterine Adenomyosis by Temporary Inhibition of Pituitary Prolactin Secretion during Youth in Mice
article
OA: closed
CC0
⤵ 12 in-corpus citations
AI-generated summary
Temporary inhibition of prolactin secretion in young mice enhanced mammary tumorigenesis but suppressed uterine adenomyosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The effects of daily subcutaneous injections of 0.2 mg CB-154 (bromocriptine-mesilate), a potent suppressor of pituitary prolactin secretion, between 4 and 11 weeks of age on the occurrence of spontaneous mammary tumors and adenomyosis, a hyperplasia of endometrial tissue, were studied in the SHN strain of virgin mice. While there was little difference in mammary tumor incidence between experimental and control mice until 9 months of age, mammary tumor incidence in the experimental mice given CB-154 was significantly enhanced and surpassed that in the control after 10 months; 25 (53.2%), 31 (66.0%), and 36 (75.5%) of 47 experimental mice and 20 (27.5%), 23 (33.3%), and 34 (49.3%) of 69 control mice developed mammary tumors at 10, 11, and 12 months of age, respectively. In contrast, no adenomyosis appeared in 39 experimental mice at necropsy at 12 months of age, while 15 (46.9%) of 32 control mice developed it. Furthermore, five mice (15.6%) of the control had numerous subserosal nodules, an advanced state of adenomyosis. No significant correlation was observed in the control mice between the occurrence of mammary tumors and that of adenomyosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (12)
- Pathological roles of prolactin signaling in gynecologic and female-predominant diseases and prospects for targeted therapy 2026
- Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies 2024
- Exploring the Endocrine Mechanisms in Adenomyosis: From Pathogenesis to Therapies 2024
- Adenomyosis: Mechanisms and Pathogenesis 2020
- Animal Models of Adenomyosis 2020
- The Pathogenesis of Adenomyosis vis-à-vis Endometriosis 2020
- Benign Uterine Diseases 2019
- The Pathophysiology of Adenomyosis 2015
- Adenomyosis 2003
- Animal model of uterine adenomyosis: Is prolactin a potent inducer of adenomyosis in mice? 1991
- Multiple Endocrine Syndrome in SHN Mice: Mammary Tumors and Uterine Adenomyosis 1989
- Suppression of normal and preneoplastic mammary growth and uterine adenomyosis with reduced growth hormone level in SHN mice given monosodium glutamate neonatally 1985
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:10:00.881616+00:00
License: CC0
· commercial use OK